Our finding that elevated cis-expression of GABRA2 is associated with increased risk of schizophrenia suggests that the change contributes to pathogenic processes rather than being simply compensatory (see also CLCN3 in the following) and suggests the possibility that targeting treatments at antagonism at this receptor complex might be more appropriate than agonism, the focus to date. Here, CLCN3 is linked to schizophrenia.